1 / 21

Ovarian hyperstimulation syndrome

Ovarian hyperstimulation syndrome. DR E.NAGHSHINEH DR.E ARSHAD. Case presentation. 31 y G1D1 Secondry infertility PMH:IVF & OHSS,IUI DH:Gonal,HMG,HCG,Metformin PSH:Laparascopy After induction ovulation :abdominal pain. Lab data. CBC(WBC:18500/Hb:15.7/HCT:46.7/PLT:290) LFT:NL

moirae
Download Presentation

Ovarian hyperstimulation syndrome

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Ovarian hyperstimulation syndrome DR E.NAGHSHINEH DR.E ARSHAD

  2. Case presentation • 31 y G1D1 • Secondry infertility • PMH:IVF & OHSS,IUI • DH:Gonal,HMG,HCG,Metformin • PSH:Laparascopy • After induction ovulation :abdominal pain

  3. Lab data • CBC(WBC:18500/Hb:15.7/HCT:46.7/PLT:290) • LFT:NL • Na:138/k:4.5 • Cr:0.9 • Alb:2.7

  4. Hospitalization • Tab Dostinex daily • Tab Cholorpheniramin • Amp Enoxaparin • Vial Alb20% TDS • Tap of ascitis:4 Lit

  5. INTRODUCTION • The most serious complication of controlled ovarian hyperstimulation.

  6. Signs and symptoms • Abdominal distention and discomfort • Enlarged ovaries • Ascites

  7. Pathophysiology • Increased capillary permeability • Loss of fluid into the third space • Overexpressionof VEGF leading to administration of hCG

  8. Two clinical forms of OHSS • The early-onset form (occurring on the first eight days after exogenous hCG administration) • The late-onset form (occurring nine or more days after hCG administration

  9. APPROACH TO MANAGEMENT

  10. Mild OHSS • Managed conservatively • With a goal of relieving symptoms • Analgesics • Avoidance of heavy physical activity

  11. Moderate OHSS • Oral fluid intake of 1 to 2 liters per day. Diuretics are contraindicated • Ambulate Avoid sexual intercourse • Daily weights • Abdominal circumference measurements • Urinary output • Transvaginalultrasound (TVUS) • Laboratory testing CBC, electrolytes, cr, serum albumin, and liver enzymes • Daily communication with patient • Ascites/culdocentesis

  12. Ascites/culdocentesis • In women with tense ascites • Orthopnea • Rapid increase of abdominal fluid

  13. The volume of fluid to be removed is not well established. • After aspiration of 500 mL: patients typically report resolution of abdominal discomfort. • Removal of more than 4 liters of fluid is not recommended.

  14. Dopamine agonists (DA) • In women at high risk for OHSS • Cabergolin (0.5 mg/day orally), beginning on the day of hCG administration or oocyteretrieval

  15. Prophylaxis for thromboembolic • All hospitalized patients with OHSS • Outpatients with two to three additional risk factors (in addition to OHSS): • Age >35 years • Obesity • Immobility • Personal or family history of thrombosis • Thrombophilias • Pregnancy

  16. Severe and critical OHSS Hospitalization • HCT >45 percent, • Leukocytes >25,000/L • Cr>1.6 mg/dL. • Severe abdominal pain • Intractable vomiting • Severe oliguria/anuria • Tense ascites • Dyspnea or tachypnea • Hypotension • Dizziness or syncope • Severe electrolyte imbalance • Abnormal LFT

  17. Isotonic crystalloid solutions ( normal saline, Ringer's lactat) • Some clinicians use intravenous albumin in critically ill, volume-depleted patients • Thromboprophylaxis • Critical OHSS cases should be managed in an ICU • Assessment of fluid balance (daily or more often) • Weights and measurement of abdominal circumference • CBC , Electrolytes ,BUN, creatinine • Serum hCG measurements (to determine if patient has conceived) • Invasive monitoring of central venous pressure • Pelvic ultrasound as needed to evaluate ovarian size and ascites • CXR and echocardiogram when pleural or pericardial effusion is suspected

  18. Resolution and prognosis Clinical evidence of resolution includes: • Normalization of hematocrit • Progressive reduction of ascites on ultrasound • Alleviation of clinical symptoms

  19. PREVENTION • Recognizing risk factors • Using individualized ovarian stimulation regimens • Modifying treatment when indicators for increasing OHSS risk develop

  20. Thanks for attention

More Related